Processing

Please wait...

Settings

Settings

Goto Application

1. MXPA/a/2001/006920 - 2-OXY-4H-3,1-BENZOXAZIN-4-ONES FOR TREATMENT OF OBESITY

Office
Mexico
Application Number PA/a/2001/006920
Application Date 06.07.2001
Publication Number PA/a/2001/006920
Publication Date 07.11.2003
Publication Kind A
IPC
A61K 31/536
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
536ortho- or peri-condensed with carbocyclic ring systems
C07D 265/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
265Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
041,3-Oxazines; Hydrogenated 1,3-oxazines
12condensed with carbocyclic rings or ring systems
14condensed with one six-membered ring
24with hetero atoms directly attached in positions 2 and 4
Applicants ALIZYME THERAPEUTICS LIMITED
Inventors HODSON, Harold, Francis
DOWNHAM, Robert
MITCHELL, Timothy, John
CARR, Beverley, Jane
CHRISTOPHER ROBERT DUNK
RICHARD MICHAEL JOHN PALMER
Agents SERGIO L. OLIVARES RODRIGUEZ
Priority Data 9900416.0 08.01.1999 GB
Title
(EN) 2-OXY-4H-3,1-BENZOXAZIN-4-ONES FOR TREATMENT OF OBESITY
(ES) DERIVADOS DE 2-AMINO-BENZOXAZINONA PARA EL TRATAMIENTO DE LA OBESIDAD
Abstract
(EN) The use of a compound comprising formula (I) or a salt, ester, amide or prodrug therof in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality, e.g. in the control and inhibition of unwanted enzymes in products and processes. The compounds are also useful in medicine e.g. in the treatment of obesity and related conditions. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I) A is a 6-membered aromatic or heteroaromatic ring;and R1 is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups.
(ES) El uso de un compuesto que comprende la fórmula (I) o una sal,éster, amida o profármaco del mismo en la inhibición de una enzima cuyo modo preferido de acción es catalizar la hidrólisis de una funcionalidad deéster, por ejemplo, en el control y la inhibición de enzimas no deseadas en los productos y procesos. Los compuestos también sonútiles en la medicina, por ejemplo, en el tratamiento de la obesidad y condiciones relacionadas. La invención también se refiere a compuestos nuevos dentro de la fórmula (I), a procesos para prepararlos y composiciones farmacéuticas que los contienen. En la fórmula (I) A es un anillo aromático o heteroaromático de 6 miembros;R1 es un alquilo ramificado o no ramificado (opcionalmente interrumpido por uno o másátomos de oxígeno), alquenilo, alquinilo, cicloalquilo, cicloalquenilo, arilo, arilalquilo, arilalquilo reducido, arilalquenilo, heteroarilo, heteroarilalquilo, heteroarilaquenilo, arilo reducido, heteroarilo reducido, heteroarilalquilo reducido o un derivado sustituido de cualquiera de los grupos precedentes.
Related patent documents
SGSG2001041441This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
NO20013380This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.